A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...

ATR 1072, a small interfering RNA drug, is Atrium's first precision cardiology program to enter the clinic since its launch earlier this year.

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...

NEW YORK – AstraZeneca has acquired worldwide rights to develop and commercialize Dizal Pharmaceutical's EGFR inhibitor Zegfrovy (sunvozertinib) for up to $1.5 billion, the company announced Tuesday.

Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...

NEW YORK – The US Food and Drug Administration on Tuesday approved Celcuity's PI3K/AKT/mTOR inhibitor Revtorpyk (gedatolisib) with fulvestrant and with or without Pfizer's Ibrance (palbociclib) for ...

NEW YORK – Eli Lilly has secured full approval for its RET inhibitor Retevmo (selpercatinib) for patients with advanced or metastatic solid tumors that harbor RET fusions, the US Food and Drug ...